Skip to content

Pediatric Myocardial Protection With Potassium Cardioplegia

Pediatric Myocardial Protection; Large Volume Potassium Cardioplegia Advantageous Over Small Volume Potassium Cardioplegia: Where do we Stand?

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03229980
Enrollment
87
Registered
2017-07-26
Start date
2017-08-10
Completion date
2018-04-28
Last updated
2018-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardioplegia

Keywords

myocardial protection, potassium cardioplegia, tropinin, Custodiol

Brief summary

The advances in cardiac surgery and anesthesia for pediatric patients planned for repair of congenital heart disease encourage us to discuss problems that occur during this surgery especially during Cardiopulmonary Bypass (CPB). Cardiopulmonary Bypass induces a damaging systemic inflammatory response, in addition to a myocardial ischemia-reperfusion injury (IRI) as a result of cessation and re-initiation of coronary artery circulation

Detailed description

After approval of the local ethics committee of Assiut University and obtaining written informed consent from parents or guardians of all patients, 60 patients with congenital heart disease will be included. Patients will be randomly allocated into three groups

Interventions

DRUGCold blood cardioplegia (large volume)

Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg

DRUGCold blood cardioplegia (small volume)

Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 6 Years
Healthy volunteers
No

Inclusion criteria

* Scheduled cardiac surgery requiring cardioplegic arrest with expected cross clamp time\>45 minutes. * Hemodynamic stability.

Exclusion criteria

* Previous cardiac surgery. * Urgent or emergent cases. * Any known allergies to components of either cardioplegia solutions.

Design outcomes

Primary

MeasureTime frameDescription
Cardiac rhythm on returnwithin the first 24 hoursSinus rhythm or Ventricular Fibrillation: DC will be used or not and if used how much joules and how many times.

Secondary

MeasureTime frameDescription
The inotropic scorewithin one month1 point is assigned for each mcg/kg/min of dopamine and dobutamine, and 10 points is assigned for each 0.1 mcg/kg/min of epinephrine, norepinephrine, and phenylephrine. (i.e. 1 point is assigned for each 10 ng/kg/min of epinephrine, norepinephrine, and phenylephrine.
Cardiac dysrhythmiaswithin the first weekCardiac dysrhythmias during intensive care unit stay
blood pressurewithin the first 24 hoursblood pressure
transthoracic echocardiography (TTE) changeswithin the first weekChanges in ejection fraction by TTE
Troponin I levelswithin the first 24 hoursWe will obtain blood samples for troponin I levels (as a marker of myocardial ischemia) pre-CBP, 6, 12 and 24 hours after the surgery.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026